Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting.
Deep brain stimulation (DBS) has assumed a prominent role in the treatment of Parkinson's disease (PD). In this manuscript, we attempt to estimate the prevalence and categorize adverse events (AEs) of DBS in PD, based on efficacy studies published over the last decade. We conclude that reliable categorization and quantification of AEs based on available data poses many challenges and argue that a standardized scheme for reporting AEs should be created. This would provide a foundation for a meaningful risk/benefit analysis, for comparison of results between centers and, ultimately, for a well informed decision by physicians and patients as to whether surgery should be pursued.
Videnovic
Aleksandar
A
Section of Movement Disorders, Rush University Medical Center, Chicago, Illinois 60612, USA. aleksandar_videnovic@rush.edu
Metman
Leo Verhagen
LV
D046690:Deep Brain Stimulation / Q000009:adverse effects / Q000379:methods* / Q000592:standards*; D005917:Globus Pallidus / Q000502:physiology / Q000528:radiation effects; D006801:Humans; D010300:Parkinson Disease / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D015995:Prevalence; D039781:PubMed / Q000706:statistics & numerical data; D012189:Retrospective Studies; D020531:Subthalamic Nucleus / Q000502:physiology / Q000528:radiation effects